Drivers of health care costs for adults with persistent asthma

J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):265-268.e4. doi: 10.1016/j.jaip.2017.05.026. Epub 2017 Jul 12.

Authors

Robert S Zeiger¹, Trung N Tran², Michael Schatz³, Qiaowu Li³, Wansu Chen³, Deepak B Khatry⁴, Jill Davis⁵, Aniket A Kawatkar³

Affiliations

¹ Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif. Electronic address: robert.s.zeiger@kp.org.
² Observational Research Center, AstraZeneca, Gaithersburg, Md.
³ Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif.
⁴ Statistical Sciences, MedImmune LLC, Gaithersburg, Md.
⁵ AstraZeneca, Wilmington, Del.

PMID: 28709819
DOI: 10.1016/j.jaip.2017.05.026

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Asthma / drug therapy
Asthma / economics
Asthma / epidemiology*
Bronchodilator Agents / therapeutic use
Disease Progression
Drug Utilization
Eosinophils / pathology*
Female
Health Care Costs / statistics & numerical data*
Humans
Male
Middle Aged
Prognosis
United States / epidemiology
Young Adult

Substances

Bronchodilator Agents